We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
- Authors
Partin, Jessica F; Mamounas, Eleftherios P
- Abstract
The development of multigene assays has proved useful in the clinical management of early-stage breast cancer. The 21-gene recurrence score (RS) assay has been shown to quantify risk of distant recurrence and predict chemotherapy benefit in node-negative and node-positive, estrogen-receptor (ER)-positive breast cancer patients. Small, single-institution series have shown that, compared with standard clinicopathologic criteria, use of RS significantly affects adjuvant chemotherapy recommendations.
- Publication
Annals of surgical oncology, 2011, Vol 18, Issue 12, p3399
- ISSN
1534-4681
- Publication type
Journal Article
- DOI
10.1245/s10434-011-1698-z